- Home
- ICCC vs FTEK Comparison
ICCC vs FTEK Comparison
Compare ICCC & FTEK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICCC
- FTEK
- Stock Information
- Founded
- ICCC 1982
- FTEK 1987
- Country
- ICCC United States
- FTEK United States
- Employees
- ICCC N/A
- FTEK N/A
- Industry
- ICCC Biotechnology: Pharmaceutical Preparations
- FTEK Pollution Control Equipment
- Sector
- ICCC Health Care
- FTEK Industrials
- Exchange
- ICCC Nasdaq
- FTEK Nasdaq
- Market Cap
- ICCC 28.7M
- FTEK N/A
- IPO Year
- ICCC 1987
- FTEK N/A
- Fundamental
- Price
- ICCC $3.55
- FTEK $1.01
- Analyst Decision
- ICCC
- FTEK Strong Buy
- Analyst Count
- ICCC 0
- FTEK 1
- Target Price
- ICCC N/A
- FTEK $4.00
- AVG Volume (30 Days)
- ICCC 20.8K
- FTEK 58.2K
- Earning Date
- ICCC 11-13-2024
- FTEK 11-05-2024
- Dividend Yield
- ICCC N/A
- FTEK N/A
- EPS Growth
- ICCC N/A
- FTEK N/A
- EPS
- ICCC N/A
- FTEK N/A
- Revenue
- ICCC $23,222,929.00
- FTEK $26,332,000.00
- Revenue This Year
- ICCC N/A
- FTEK $8.36
- Revenue Next Year
- ICCC N/A
- FTEK $6.35
- P/E Ratio
- ICCC N/A
- FTEK N/A
- Revenue Growth
- ICCC 48.05
- FTEK N/A
- 52 Week Low
- ICCC $3.34
- FTEK $0.91
- 52 Week High
- ICCC $5.59
- FTEK $1.34
- Technical
- Relative Strength Index (RSI)
- ICCC 43.90
- FTEK 48.28
- Support Level
- ICCC $3.51
- FTEK $1.00
- Resistance Level
- ICCC $3.74
- FTEK $1.05
- Average True Range (ATR)
- ICCC 0.17
- FTEK 0.04
- MACD
- ICCC 0.00
- FTEK -0.00
- Stochastic Oscillator
- ICCC 18.60
- FTEK 37.50
About ICCC ImmuCell Corporation
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.